Ozmosi | Bafetinib Drug Profile

Product Description

An orally bioavailable 2-phenylaminopyrimidine derivative with potential antineoplastic activity. Bafetinib specifically binds to and inhibits the Bcr/Abl fusion protein tyrosine kinase, an abnormal enzyme produced by Philadelphia chromosomal translocation associated with chronic myeloid leukemia (CML). (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bafetinib)

Mechanisms of Action: Bcr-Abl Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: CytRx
Company Location: LOS ANGELES CA 90049
Company CEO: Stephen Snowdy
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Prostate Cancer|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia

Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
BAFETINIB-P1-GBM-01	P1	Completed	Astrocytoma\|Glioblastoma\|Ependymoma\|Oligodendroglioma\|Giant Cell Tumors\|Gliosarcoma\|Brain Cancer	2013-03-01	2019-03-19	Treatments
INNO-406	P1	Completed	Acute Lymphoid Leukemia\|Chronic Myeloid Leukemia\|Chronic Lymphoid Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Acute Myeloid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2008-05-01	2019-03-21	Treatments
BAFETINIB-P2-CLL-01	P2	Completed	Lymphocytic Chronic B-Cell Leukemia\|Chronic Lymphoid Leukemia	2011-12-01	2019-03-19	Treatments
PROACT	P2	Completed	Prostate Cancer	2011-09-01	2019-03-19	Treatments

Recent News Events

Date	Type	Title
11/20/2023	PubMed	Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.
11/16/2023	PubMed	Target deconvolution with matrix-augmented pooling strategy reveals cell-specific drug-protein interactions.
09/08/2023	PubMed	Tyrosine Kinase Inhibitor Profiling Using Multiple Forskolin-Responsive Reporter Cells.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Bafetinib

Alternative Names: bafetinib, inno-406 Clinical Status: Inactive Latest Update: 2023-11-20 Latest Update Note: PubMed Publication